> QUERY LOG / 06
Frequently asked questions about tesamorelin
Direct, cited answers to the questions people actually ask — what tesamorelin does, how much fat the trials measured, what happens when you stop, and where the FDA approval begins and ends.
Will tesamorelin help me lose belly fat?
In the pivotal 26-week Phase 3 RCT of 412 HIV patients with abdominal fat accumulation, tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% while placebo rose 5.0% [1]. The studied population was HIV-associated lipodystrophy; effects on general belly fat outside that population are not established by large trials, so this is a documented result, not a personal projection.
How long does it take to see fat loss from tesamorelin?
Trials measured visceral-fat reduction over 26 weeks, with the reduction sustained at 52 weeks on continued dosing [1][2]. The 2026 five-RCT meta-analysis pooled visceral, trunk, and hepatic-fat changes across these multi-month treatment periods [13]. The effect is a months-long, imaging-measured shift — there is no published evidence for a rapid weeks-scale change.
Does tesamorelin burn belly fat?
Tesamorelin selectively reduced visceral adipose tissue (the fat around the organs) in HIV-lipodystrophy trials by raising endogenous GH and IGF-1, which promote lipolysis [1]. It did not significantly change subcutaneous fat or BMI in those studies [1] — the effect is a redistribution measured by imaging, concentrated in visceral fat rather than overall weight.
Does tesamorelin work for fat loss in non-HIV users?
Pivotal efficacy trials enrolled HIV-positive adults on antiretroviral therapy [1][2]. A small mechanistic study in 13 healthy men confirmed GH/IGF-1 elevation [4], but no large general-population fat-loss RCT has been completed, so non-HIV fat-loss efficacy is mechanistically plausible but not established by trial evidence.
What happens when you stop taking tesamorelin? Does the fat come back?
In the 52-week program, visceral fat reaccumulated upon discontinuation [2], and the Phase 3 trial with a safety extension likewise reported reversal of the visceral-fat reduction after stopping [6]. The measured benefit was contingent on continued dosing — the imaging gains revert toward baseline once the drug is withdrawn.
How much fat can I lose on tesamorelin?
The pivotal trial reported a 15.2% visceral-fat reduction at 26 weeks [1]; a pooled analysis of two Phase 3 RCTs found 3.9-fold greater odds of reducing visceral fat below 140 cm² versus placebo (95% CI 2.03–7.44) [10]. These magnitudes are from the studied HIV-lipodystrophy population, not a personal projection.
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone, GHRH(1-44), with an N-terminal trans-3-hexenoic acid group that resists DPP-IV cleavage [1]. It stimulates the body's own pulsatile GH and raises IGF-1, and is FDA-approved only to reduce excess abdominal fat in HIV-associated lipodystrophy [5].
What does tesamorelin do?
It binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous growth-hormone secretion, which raises liver-produced IGF-1 and promotes lipolysis preferentially in visceral fat [4]. The FDA-approved use is reducing excess abdominal fat in HIV-associated lipodystrophy [5]; all other uses are off-label.
Does tesamorelin increase the risk of diabetes or affect blood sugar?
In 13 healthy men, neither fasting glucose nor insulin-stimulated glucose uptake changed significantly [4]; over 52 weeks in HIV patients, glucose changes were not clinically significant [2]. GH-axis stimulation can perturb glucose modestly, so monitoring is described for people with prediabetes or dysglycemia.
Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?
A 6-month JAMA RCT in antiretroviral-treated HIV adults reduced hepatic lipid by a net -2.9% alongside visceral-fat reduction [3]. NAFLD/MASLD effects have been studied as a research endpoint in the HIV population, not as an FDA-approved indication outside it.
How does tesamorelin affect the liver in NAFLD?
In the JAMA HIV trial, tesamorelin reduced hepatic fat as visceral fat fell [3]; the proposed mechanism couples GH/IGF-1-driven lipolysis with hepatic gene-expression shifts (upregulated oxidative phosphorylation, downregulated inflammatory sets) [3]. Long-term liver-histology effects were noted as needing further study.
Can tesamorelin reduce liver fat?
In the 6-month JAMA RCT of 50 HIV adults, tesamorelin produced a net hepatic-fat reduction of -2.9% (P=0.003) [3], and the 2026 five-RCT meta-analysis pooled hepatic-fat reduction at -4.28% [13]. Liver-fat reduction has been demonstrated as a research endpoint specifically in HIV-associated fatty liver.
What is the half-life of tesamorelin?
Secondary sources (the FDA label, Mayo Clinic) describe a terminal half-life on the order of about 26–38 minutes. Despite that rapid plasma clearance, downstream IGF-1 elevation persists across the dosing interval, which supports once-daily administration [11].
How long does tesamorelin stay in your system?
Plasma exposure is short: population-PK modeling estimated apparent clearance near 1,060 L/h with no clinically relevant demographic covariates [11]. The biological signal (IGF-1) outlasts plasma drug levels because tesamorelin stimulates episodic GH secretion rather than acting as a circulating reservoir [11].
What are the side effects of tesamorelin?
The FDA label warns about stimulating endogenous GH and raising serum IGF-1; injection-site reactions are reported in the GH-secretagogue class. The NIH LiverTox monograph assigns a likelihood score of E (unlikely cause of clinically apparent liver injury), with no reported attributable liver-injury cases [5].
Does tesamorelin cause water retention?
Fluid-related effects are part of the broader growth-hormone-class warning profile noted in the FDA label, which cautions about stimulating endogenous GH. The trial literature emphasizes visceral-fat and glucose endpoints [1][2] rather than isolating fluid retention as a measured outcome.
Who should not take tesamorelin / who should avoid it?
The FDA prescribing label lists contraindications including any preexisting active malignancy (IGF-1 is a growth factor), known hypersensitivity to tesamorelin or its excipients, and pregnancy (animal studies showed hydrocephaly in offspring) [5]. It is also prohibited in sport under the WADA Prohibited List (category S2).
Is tesamorelin FDA approved?
Yes, but only for one indication: tesamorelin was approved in the United States in 2010 (NDA 022505) to reduce excess abdominal fat in HIV-infected patients with antiretroviral-related lipodystrophy [5]. Every other use — cosmetic weight loss, anti-aging, non-HIV fat loss — is off-label.
Does tesamorelin raise IGF-1 levels?
Yes. In 13 healthy men, tesamorelin raised IGF-1 by 181 µg/L (P<0.0001) [4]; in the pivotal HIV trial IGF-1 increased 81.0% [1]. IGF-1 elevation is the expected downstream signal of GH-axis stimulation and is the most consistent biomarker readout across the studies.
How does tesamorelin stimulate growth hormone release?
It binds the GHRH receptor on pituitary somatotrophs and triggers cAMP/PKA signaling that drives pulsatile GH secretion [4]. Population PK-PD modeling confirmed tesamorelin stimulates GH in an episodic, pulse-like manner rather than continuously [11], which distinguishes its profile from recombinant growth hormone.
Is tesamorelin a growth hormone?
No. Tesamorelin is a GHRH analogue, not growth hormone itself; it amplifies the body's own pulsatile GH rhythm rather than supplying exogenous GH [11]. That mechanism — triggering an internal pulse rather than clamping a continuous level — distinguishes its metabolic profile from recombinant growth hormone.
How does tesamorelin work?
Tesamorelin activates the Gs/adenylyl-cyclase/cAMP/PKA cascade at the GHRH receptor, driving GH gene transcription and pulsatile GH release [4]. GH then stimulates hepatic IGF-1, and together they activate hormone-sensitive lipase to break down visceral fat [4] — the cascade detailed on the research page.